A systematic review and meta-analysis to evaluate blood levels of interleukin-6 in lung cancer patients.

IF 0.6 Q4 SURGERY
Kardiochirurgia I Torakochirurgia Polska Pub Date : 2023-12-01 Epub Date: 2024-01-11 DOI:10.5114/kitp.2023.134177
Seyed Vahid Jasemi, Soha Zia, Seyed Ghasem Mirbahari, Masoud Sadeghi
{"title":"A systematic review and meta-analysis to evaluate blood levels of interleukin-6 in lung cancer patients.","authors":"Seyed Vahid Jasemi, Soha Zia, Seyed Ghasem Mirbahari, Masoud Sadeghi","doi":"10.5114/kitp.2023.134177","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The exact mechanism responsible for inflammation in malignancy is not completely understood, but it is possible that interleukin-6 (IL-6) plays a major role in triggering and maintaining an inflammatory response.</p><p><strong>Aim: </strong>To conduct a systematic review and meta-analysis of the levels of IL-6 in the serum/plasma of lung cancer (LC) patients.</p><p><strong>Material and methods: </strong>The researchers searched four databases up to September 11, 2022, to find studies that reported on IL-6 levels in LC patients compared to healthy controls (HCs). They calculated effect sizes using standardized mean difference (SMD) with a 95% confidence interval (CI). To evaluate the quality of each study, they used the Newcastle-Ottawa Scale (NOS). They performed subgroup analysis, sensitivity analysis, meta-regression analysis, heterogeneity analyses, trial sequential analysis, and publication bias with the trim-and-fill method.</p><p><strong>Results: </strong>The meta-analysis included 28 studies, and the results showed that the pooled SMD was 1.71 (95% CI: 1.22, 2.19; <i>p</i> < 0.00001; <i>I</i><sup>2</sup> = 98%), indicating that LC patients had significantly higher levels of IL-6 in their serum/plasma than HCs.</p><p><strong>Conclusions: </strong>The study found that the publication year and quality score of the studies were positively associated with the level of IL-6, while the sample size was inversely related. The research suggests that measuring IL-6 levels in the blood could be useful for detecting and monitoring LC as it appears to be a reliable biomarker.</p>","PeriodicalId":49945,"journal":{"name":"Kardiochirurgia I Torakochirurgia Polska","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809806/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiochirurgia I Torakochirurgia Polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/kitp.2023.134177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The exact mechanism responsible for inflammation in malignancy is not completely understood, but it is possible that interleukin-6 (IL-6) plays a major role in triggering and maintaining an inflammatory response.

Aim: To conduct a systematic review and meta-analysis of the levels of IL-6 in the serum/plasma of lung cancer (LC) patients.

Material and methods: The researchers searched four databases up to September 11, 2022, to find studies that reported on IL-6 levels in LC patients compared to healthy controls (HCs). They calculated effect sizes using standardized mean difference (SMD) with a 95% confidence interval (CI). To evaluate the quality of each study, they used the Newcastle-Ottawa Scale (NOS). They performed subgroup analysis, sensitivity analysis, meta-regression analysis, heterogeneity analyses, trial sequential analysis, and publication bias with the trim-and-fill method.

Results: The meta-analysis included 28 studies, and the results showed that the pooled SMD was 1.71 (95% CI: 1.22, 2.19; p < 0.00001; I2 = 98%), indicating that LC patients had significantly higher levels of IL-6 in their serum/plasma than HCs.

Conclusions: The study found that the publication year and quality score of the studies were positively associated with the level of IL-6, while the sample size was inversely related. The research suggests that measuring IL-6 levels in the blood could be useful for detecting and monitoring LC as it appears to be a reliable biomarker.

评估肺癌患者血液中白细胞介素-6水平的系统综述和荟萃分析。
导言:目的:对肺癌(LC)患者血清/血浆中的IL-6水平进行系统综述和荟萃分析:研究人员检索了截至2022年9月11日的四个数据库,以找到有关肺癌患者与健康对照组(HCs)IL-6水平比较的研究报告。他们使用标准化均值差异(SMD)和95%置信区间(CI)计算效应大小。为了评估每项研究的质量,他们使用了纽卡斯尔-渥太华量表(NOS)。他们采用修剪填充法进行了亚组分析、敏感性分析、元回归分析、异质性分析、试验序列分析和发表偏倚分析:荟萃分析纳入了28项研究,结果显示,汇总的SMD为1.71(95% CI:1.22,2.19;P < 0.00001;I2 = 98%),表明LC患者血清/血浆中的IL-6水平显著高于HC:研究发现,研究的发表年份和质量评分与 IL-6 水平呈正相关,而样本量则呈反相关。研究表明,测量血液中的 IL-6 水平有助于检测和监测 LC,因为它似乎是一种可靠的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
14.30%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Polish Journal of Thoracic and Cardiovascular Surgery is a quarterly aimed at cardiologists, cardiosurgeons and thoracic surgeons. Includes the original works (experimental, research and development), illustrative and casuistical works about cardiology and cardiosurgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信